Earnings per share for the last twelve months: sunshinebiopharma.com (SBFM)
Sunshine Biopharma develops RNA therapies and small molecules to combat resistant gastrointestinal cancers. The rolling annual earnings per share visualizes financial efficiency, while the -170.82 metric reflects current dynamics. Sunshine Biopharma combines the sale of generics with research and development alliances. The brand's high authority is based on the pursuit of innovative treatments for severe viral and oncological pathologies.
Summary analytical data breakdowns for Sunshine Biopharma Inc. (SBFM)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Sunshine Biopharma|SBFM - Long-Term Debt to Capital|Short-Term Debt to Equity Sunshine Biopharma, Inc.|SBFM - Company Aggregate Debt|Debt to Book Capitalization Ratio Sunshine Biopharma|SBFM - Long-Term Debt Volume|Company Short-Term Debts Sunshine Biopharma|Quick Ratio sunshinebiopharma.com
- net income and valuation multiples indicators:
SBFM - Net Financial Result|Expected Profit Sunshine Biopharma|SBFM - Price to Earnings Multiple|Forward P/E Multiple sunshinebiopharma.com|SBFM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Sunshine Biopharma, Inc.|SBFM - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Sunshine Biopharma|SBFM - Earnings per share for the last twelve months|Quarterly EPS earnings growth sunshinebiopharma.com|SBFM - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Sunshine Biopharma
- revenue and sales proceeds data:
Fundamental valuation:SBFM - sunshinebiopharma.com
Long-term asset selection requires rigorous screening of an issuer's operational efficiency. This indicator calculates net income allocated per common share per year, reflecting the business's actual unit profitability. For Sunshine Biopharma (SBFM), whose oncology developments remain independent of macroeconomic cycles, this parameter serves as a benchmark for patent commercialization. Analyzing the 12-month net income per share snapshot helps eliminate debt risks. Investors should utilize this chart to assess margin sustainability.
Competitors of Sunshine Biopharma
ONC - Earnings per share for the last twelve months|HALO - Net earnings per share (EPS TTM)|RevMed (RVMD) - Earnings per share for the last twelve months|Ascentage - Earnings per share for the trailing year|CGON (CG Oncology Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma URGN|Net earnings per share (EPS TTM) BCAX|PSNL: Earnings per one share for the last 12 months|Earnings per share for the last twelve months Erasca Corp ERAS|Delcath Corp (DCTH) - Net earnings per one share for the last twelve months|YMAB - Earnings per share for the last twelve months|Earnings per share for the trailing year AURA (Aura Biosciences, Inc.)|CADL: Net earnings per share (EPS TTM)|Accuray Inc (ARAY) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months SELLAS Life Sciences Group|Net earnings per share (EPS TTM) Actuate Therapeutics, Inc.|Earnings per share for the last twelve months citiusonc.com (CTOR)|Net earnings per share (EPS TTM) TuHURA (HURA)|Net earnings per share (EPS TTM) TARA (protaratx.com)|Earnings per share for the trailing year FATE|WHWK - Earnings per share for the last twelve months|Earnings per share for the trailing year TCRX (tscan.com)|Champions Oncology (CSBR) - Earnings per share for the last twelve months|XBiotech Inc - Earnings per share for the trailing year|Earnings per share for the last twelve months cel-sci.com|OS Therapies (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|Earnings per share for the last four quarters ARTV|Adlai Nortye Ltd. - Net earnings per share for the last 12 months|Earnings per share for the trailing year VERU|tempesttx.com - Net earnings per share (EPS TTM)|XLO - Net earnings per share (EPS TTM)|Enochian BioSciences (RENB) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Mural Oncology plc (MURA)|Earnings per share for the last twelve months Kairos Pharma Ltd|Net earnings per share (EPS TTM) OnKure Therapeutics|Net earnings per share for the last 12 months GDTC (w2.cytomed.sg)|Net earnings per share (EPS TTM) Curis Inc. (CRIS)|Earnings per share for the last twelve months Apollomics Inc. APLM|Earnings per share for the trailing year THAR|ADVB - Earnings per share for the last twelve months|GNPX - Net earnings per share (EPS TTM)|CLDI (calidibio.com) - Net earnings per share for the last 12 months|XBIO - Net earnings per share for the last four quarters|SLRX (Salarius Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Kitov Pharma|Net earnings per share for the last 12 months AONC (American Oncology Network)|BGNE - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CKPT (Checkpoint Therapeutics Inc.)|Elevation Oncology, Inc. - Earnings per share for the last twelve months|ICAD - Earnings per share for the last twelve months|IKNA - Net earnings per share (EPS TTM)|Notable Labs (NTBL) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIRX|MOR (MorphoSys Corporation) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NAYA Biosciences Inc NAYA|Earnings per share for the last twelve months Ascentage Pharma (AAPGV)
